Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
주식 순위
#4336
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
주가
$3.87
시가총액
$3.57B
변동 (1일)
-1.64%
변동 (1년)
9.08%
국가
CN
거래 Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
카테고리
Healthcare
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)의 발행 주식 수
October 2026 기준 발행 주식 수: 0
Hubei Jumpcan Pharmaceutical Co., Ltd.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 0입니다. October 2026 말 기준 회사는 0주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)의 발행 주식 수 기록 (2001 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2025 | 921.17M | 0.43% |
| 2024 | 917.23M | 0.08% |
| 2023 | 916.49M | 3.02% |
| 2022 | 889.65M | 0.16% |
| 2021 | 888.27M | 6.41% |
| 2020 | 834.78M | 2.44% |
| 2019 | 814.92M | 0.43% |
| 2018 | 811.47M | 0.23% |
| 2017 | 809.62M | 1.40% |
| 2016 | 798.45M | 2.34% |
| 2015 | 780.19M | 0.64% |
| 2014 | 775.21M | 27.04% |
| 2013 | 610.19M | 0.13% |
| 2012 | 609.41M | 341.10% |
| 2011 | 138.16M | -0.09% |
| 2010 | 138.28M | 30.05% |
| 2009 | 106.32M | -23.09% |
| 2008 | 138.24M | 0.03% |
| 2007 | 138.21M | 0.12% |
| 2006 | 138.05M | 0.00% |
| 2005 | 138.05M | 0.00% |
| 2004 | 138.05M | 0.00% |
| 2003 | 138.05M | 0.00% |
| 2002 | 138.05M | 0.00% |
| 2001 | 138.05M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
